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Abstract
Objective: Deep brain stimulation (DBS) has been used for more than a decade to treat Parkinson’s disease (PD); however,
its mechanism of action remains unknown. Given the close proximity of the electrode trajectory to areas of the brain known
as the ‘‘germinal niches,’’ we sought to explore the possibility that DBS influences neural stem cell proliferation locally, as
well as more distantly.
Methods: We studied the brains of a total of 12 idiopathic Parkinson’s disease patients that were treated with DBS (the
electrode placement occurred 0.5–6 years before death), and who subsequently died of unrelated illnesses. These were
compared to the brains of 10 control individuals without CNS disease, and those of 5 PD patients with no DBS.
Results: Immunohistochemical analyses of the subventricular zone (SVZ) of the lateral ventricles, the third ventricle lining,
and the tissue surrounding the DBS lead revealed significantly greater numbers of proliferating cells expressing markers of
the cell cycle, plasticity, and neural precursor cells in PD-DBS tissue compared with both normal brain tissue and tissue from
PD patients not treated with DBS. The level of cell proliferation in the SVZ in PD-DBS brains was 2–6 fold greater than that in
normal and untreated PD brains.
Conclusions: Our data suggest that DBS is capable of increasing cellular plasticity in the brain, and we hypothesize that it
may have more widespread effects beyond the electrode location. It is unclear whether these effects of DBS have any
symptomatic or other beneficial influences on PD.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder causing
debilitating tremor, rigidity, bradykinesia and gait disorders and
can affect non-motor circuits, causing depression, anxiety and
sexual dysfunction [1,2]. Current treatment options for PD
including dopamine replacement (levodopa and dopamine ago-
nists) and surgery (thalamotomy, pallidotomy) only provide
symptomatic relief and are not curative. Deep brain stimulation
(DBS) is a surgical procedure where leads are stereotactically
implanted to reach a specific neural target (subthalamic nucleus
(STN), globus pallidus internus (GPi)) and are programmed to
deliver chronic electrical stimulation [3,4,5]. Close to the lead
placement are the germinal zones, the subventricular zone [SVZ]
and subgranular zone [SGZ], containing neural stem cells (NSCs)
[6,7,8]. NSCs can generate new neurons throughout life, which
occurs in neurologically normal brains [7], and is increased after
neurodegeneration (Huntington’s disease, stroke etc) [6,9,10,
11,12,13,14,15,16,17,18]. In PD, a reduction in SVZ dopaminer-
gic innervation results in decreased precursor proliferation [19],
although this has been recently challenged [20]. Since the
trajectories necessary to reach the target nuclei traverse close to
the lateral and third ventricles [21] we investigated the effects of
DBS on neural precursor cell proliferation in the SVZ of the third
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ventricle and distal lateral ventricle regions. We analyzed the
numbers of cells in the SVZ, third ventricle lining and electrode
region expressing markers of neural precursor cells in normal, PD
and PD-DBS brains. In all PD-DBS cases the DBS electrode was
chronically implanted and it was more than a year between
placement and death. Our results demonstrate a significant
increase in the numbers of SVZ neural precursor cells in the
ventricles and the area of electrode placement in PD-DBS brains.
Materials and Methods
All protocols used in these studies were approved by the
University of Auckland and the University of Florida Human
Participants Ethics committees and informed consent was
obtained from all donor families (UF-IRB Project # 130-2008).
Tissue from post-mortem human brains used in this study was
obtained from one of the following sources: (1) the Neurological
Foundation of New Zealand Brain Bank at the Department of
Anatomy with Radiology, University of Auckland; (2) DBS tissue
samples from the University of Florida Deep Brain Stimulation
Brain Tissue Network; or (3) Arizona Parkinson’s disease Brain
Bank (AZPDB), Sun Valley, Arizona (for details of which cases
were from each source, see Table 1). Taken together, the normal
cases (n = 10) had a mean age of 76.665.9, PD with DBS cases
(n = 12) had a mean age of 71.666.0, and PD only cases (n = 5)
had a mean age of 80.264.2. The normal cases were chosen based
on the pathology reports (neuropathological examination was
carried out on each case by an experienced neuropathologist) that
classified the cases as within the normal range for their age with no
signs of neuropathological or histological abnormalities. Addition-
ally, the cases were similarly aged, relatively young by human
brain study standards and had similar causes of death. The
pathology reports for all normal cases revealed that no atrophic
changes were observed in the frontal, lateral temporal, hippocam-
pal or cingulate cortices; that there were no plaques or vascular
amyloid and no neurofibrillary tangles or excessive glial staining
seen with an immunoperoxidase tau stain; that no indications of
cortical or nigral Lewy body formation were seen; that there were
no infarcts and the small arteries showed no sclerotic changes; that
the corpus striatum was unremarkable; and that no significant
histological abnormalities were found. The five PD patients
without DBS had a clinical history of PD, and the diagnosis of
the disease was confirmed by pathological examination. The PD
patients subjected to unilateral or bilateral DBS treatment (details
of electrode placement are presented in Table 1) had clinically
diagnosed PD and pathological examination confirmed the
pathology in all cases. Not all brain regions were available for
all brains. We chose the cases that had been optimally fixed for
each specific study and for which sufficient brain tissue was
available to ensure consistency of anatomical region in each case.
Because there are regional differences in SVZ proliferation we
needed to use blocks that were fixed in the same way and that
displayed key anatomical components at previously described. For
this reason not all cases were used for counting the progenitor cells
in the SVZ. The brains were perfused with PBS containing 1%
sodium nitrite followed by 15% formalin fixative in 0.1 M
phosphate buffer pH 7.4 for 24 hours. Following perfusion, the
brains were dissected, and blocks from the basal ganglia were post-
fixed, infiltrated with 30% sucrose and sectioned on a freezing
microtome at 50-mm thickness for the cell counting studies in the
SVZ. Immunohistochemistry was performed using proliferating
cell nuclear antigen (rabbit PCNA – FL-261: Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA; 1:500) antibody to
identify proliferating stem cells in the SVZ. The SVZ overlying the
caudate nucleus was divided into equal dorso-ventral thirds, and
detailed cell counts of PCNA-positive cells were made at dorsal,
middle, and caudal areas of the SVZ as previously described [11].
For the detailed regional cell counting studies, the cases numbered
1–9 on table 1 were used. Two observers blinded to the disease
status, area, region and brain from which the image was taken
counted the numbers of PCNA-positive cells. Cells were counted
from digitised micrographs using ImageJ software. Three rectan-
gular background measurements were taken from areas of the
section that did not contain PCNA-positive cells and the
background staining from each of these rectangles was averaged.
Each cell in the micrograph had a dot placed on it so that no cell
was counted twice. Also, a density measurement was taken from
the point the dot was located, and recorded for each cell counted.
Density measurements, which ranged from 0 to 255 (where
0 =white and 255= black) were made for each cell; in order for
the cell to be counted it had to have a density measurement value
of 25 density points higher than the average background
measurement. This technique ensured that cells were not included
or excluded from the cell counts based on the background density
or intensity respectively. Each area sample area was 400 mm in
length and cells were counted with the observer blinded to the
location and disease status from which the sample was taken.
The counts from five consecutive sections per case were
accumulated and the mean cell number is presented. Identical
anatomical landmarks and procedures were used as previously
described by us and only SVZ cells were counted; therefore,
ependymal cells did not contribute to the numbers of cells counted
[11]. The cell numbers presented here are the average cell number
counted in a fixed volume as previously described [11]. The data
resulting from the cell counts were analyzed using Prism Version
X (Graphpad Software, Palo Alto, CA). A permutation test was
performed to compare normal and DBS brains in all regions. The
quoted (displayed) values are the means and standard error of the
mean for each group. A p-value of less than 0.05 was considered
significant. For the tissue purchased from AZPDB, as well as the
tissue obtained from the AZPDB, blocks of paraffin-embedded
tissue (2 cm62 cm) from the same anatomical region (subthalamic
nucleus at the level of the hypothalamus including a portion of the
lining of the third ventricle, and the termination of the electrode
lead tip respectively; Table 1) of dissected PD-DBS and control
brains were obtained. Eight-micron-thick sections were cut on a
microtome (Leica RM 2235) and mounted on coated slides for
analysis. For immunohistochemistry, the following primary
antibodies were used: Sox2 (mouse, R&D, 1:500, MAB 2018),
MCM2 (rabbit, Cell Signaling, 1: 500, D7G11), and d-GFAP
(rabbit, a generous gift from Dr. Elly Hol, Netherlands Institute for
Neuroscience, 1:1500). Secondary antibodies used were Alexa
Fluor 488 donkey anti-mouse IgG (A-21202) and anti-rabbit
(A-21206).
Slides were mounted with Vectashield (Vector Labs, H-1200),
and analyzed using a Leica DM 2500 fluorescence microscope.
Direct comparisons were never made between these 8-mm sections
and the 50-mm sections described above. Detailed cell counts of
Sox2- and d-GFAP-positive cells from two sections per case were
made at the caudal area of the third ventricle lining. Cell counts of
MCM-2-positive cells were made in the region immediately
surrounding the electrode lead tip. All statistics were performed
using a two-sample permutation test, using the difference in means
for each group as the test value.
qPCR
Four 20-mm sections from each control and PD-DBS brain,
from the same anatomical region as described above, were cut on
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a microtome (Leica RM 2235). The samples were immediately
collected in RNAase-free tubes containing xylene and processed
for mRNA extraction using the Qiagen FFPE RNA extraction kit
(Qiagen, 74404). The concentration of total RNA extracted was
measured using a Nanodrop 2000 (ThermoScientific). Only
samples with a ratio of absorbance at 260 and 280 nm (A260/
280 ratio) of over 1.85 were used for PCR. Following RT-PCR,
qPCR using Taqman qPCR primers (Applied Biosystems, Foster
City, CA) was performed for the following human genes: MCM2
and Sox2 and the housekeeping gene 18S using Sox2, and MCM2
Taqman gene expression assay kits (Hs01053049_s1 and
Hs01091564_m1). Samples were assayed on a real-time qPCR
cycler (7900HT, Applied Biosystems) in 96-well optical plates
covered with caps. The comparative CT method (DDCT) was
employed to determine relative gene level differences between
control and DBS tissue, and gene expression was normalized
against that for the housekeeping gene 18S.
Table 1. Table of cases used in this study showing case number, brain bank the tissue was from, sex, age, stimulator lead
placement and side of the brain on which the lead was placed.
BRAIN
TYPE CASE ORIGIN USAGE AGE SEX PM-DELAY PLACEMENT
DBS to
DEATH
1 PD-DBS DBS25 NZBB CC 64 M 24 GPi Bilateral 1 y
2 PD-DBS DBS195 FDBSTN CC 67 M 4 STN Bilateral 5 y
3 PD-DBS DBS204 FDBSTN CC 69 M unknown STN Bilateral 6 y
4 PD-DBS DBS205 FDBSTN CC 64 F ,24 GPi Bilateral 6 y R, 1 y L
5 PD-DBS DBS208 FDBSTN CC 65 M ,12 GPi Left 2 y
6 PD-DBS DBS210 FDBSTN CC 70 M 17 STN Bilateral 0.5 y R, 2 y L
7 PD-DBS DBS211 FDBSTN CC 73 M unknown VIM Left 13 y
8 PD-DBS DBS212 FDBSTN CC 81 F ,24 STN Bilateral 5 y R, 6 y L
9 PD-DBS DBS213 FDBSTN CC 78 M ,24 STN Left 3 y
10 PD-DBS 08-70R AZPDB CC+PCR/3V+T 75 M ,4 STN Bilateral 2 y R, 2 y L
11 PD-DBS 08-74L/R AZPDB CC+PCR/3V+T 79 F 3.1 STN Bilateral 3 y R, 3 y L
12 PD-DBS 07-36L/R AZPDB CC+PCR/3V+T 75 M ,4 STN Bilateral 4 y R, 4 y L
13 PD PD24 NZBB CC 74 M 7
14 PD PD26 NZBB CC 78 M 7.5
15 PD PD37 NZBB CC 81 M 4
16 PD PD42 NZBB CC 84 M 21
17 PD PD52 NZBB CC 84 M 5
18 Normal H151 NZBB CC 64 F 5
19 Normal H156 NZBB CC 71 M 19
20 Normal H158 NZBB CC 75 M 32
21 Normal H393 NZBB CC 87 F 11
22 Normal H6013 NZBB CC 69 F 11.5
23 Normal 08-90 AZPDB CC+PCR/3V 81 M 2.3
24 Normal 06-62 AZPDB CC+PCR/3V 82 F ,5
25 Normal 08-40 AZPDB CC+PCR/3V 76 M 2.3
26 Normal 06-66 AZPDB CC+PCR 78 M ,5
27 Normal 08-55 AZPDB CC+PCR 71 M 3
‘3v’ indicates that tissue was available from the third ventricle and ‘T’ indicates that tissue from these cases was available from the tip of the stimulator lead.
Immunohistochemistry was performed on all brains.
PD-DBS = Parkinson’s disease with deep brain electrode placement.
PD= Parkinson’s disease.
CC = cell counting.
PCR= polymerase chain reaction.
3V = third ventricle tissue was available and used.
T = tissue from electrode tip was available and used.
NZBB =New Zealand Brain Bank.
FDBSTN=University of Florida Deep Brain Stimulation Tissue Network.
AZPDB=Arizona Parkinson’s Disease Bank.
GPi = internal segment of the globus pallidus.
STN= subthalamic nucleus.
VIM= ventrointermediate nucleus of the thalamus.
y = years.
R = right side.
L = left side.
doi:10.1371/journal.pone.0088770.t001
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Results
Detailed analyses of the numbers of PCNA-positive cells in the
SVZ adjacent to the caudate nucleus were performed on a total of
five normal, five PD and nine PD-DBS brains. In eight of the nine
PD-DBS cases, and in one of the five normal brains, both
hemispheres were available for study, although no significant
difference was seen between left and right (P = 0.279 dorsal and
P=0.410 middle). The dorsal measurements were made from the
center of the dorsal 1/3rd of the lateral ventricle and the middle
measurements were made from the middle of the middle 1/3rd of
the lateral ventricle. For more detail on the anatomical localiza-
tions of the regions used for these cell counts see [11]. The average
of cell counts from the left and right hemisphere was used for this
analysis. The overall mean number of PCNA-positive cells in the
SVZ adjacent to the caudate nucleus of PD brains was not
significantly different from that in normal brains, but only five PD
non-DBS cases were available (Figure 1b). However, there were
significantly more PCNA-positive cells in PD-DBS brains (mean6
SEM; dorsal 60.4610.71; middle 71.14612.68) compared with
normal brains (dorsal 17.565.80, P= 0.0252; middle 26.669.801;
P = 0.0303). There was also a significant difference in the number
of PCNA-positive cells between PD and PD-DBS cases (PD dorsal
10.765.8, P= 0.011; middle 11.268.6, P= 0.015; Figure 1b–e).
This corresponded to a 345% (dorsal) and 267% (middle) higher
level of proliferation in the PD-DBS SVZ compared with the
normal SVZ, respectively. PCNA immunohistochemical labeling
of the PD-DBS brains also revealed an expanded SVZ adjacent to
the caudate nucleus as compared with normal and untreated PD
brains. Many of the PCNA-positive cells in the SVZ were also
immunopositive for glial fibrillary acidic protein delta (d-GFAP)
(Figure 1f–i).
We then asked whether this higher level of proliferation was
exclusive to the highly proliferative SVZ lining the lateral
ventricle, or whether such proliferation was a common feature
of other areas closely related to the DBS electrode. Owing to the
close proximity of the electrode tip to the other neurogenic niche,
namely, the third ventricle lining, we chose to study this area and
the peri-lead region. Using tissue obtained from the AZPDB, we
studied the numbers of proliferating and quiescent precursor cells
in the region immediately surrounding the lead tip in PD-DBS
human brains (n = 5 hemispheres from 3 cases), and compared
them to the numbers in the same regions in normal brains (n = 5).
In addition, we quantified the numbers of proliferative precursor
cells in the SVZ of the relatively less-studied, but still neurogenic,
third ventricle lining (at the level of the hypothalamus) in a subset
of brains (case numbers 10–12 and 23–25 in table 1) [22,23]. This
comparison was performed using three markers to label different
populations of cells: Sox2 (a transcription factor expressed by
precursor cells destined to become glial cells), d-GFAP (an
intermediate filament protein expressed in a subpopulation of
astrocytes in the adult human brain ventricles that are putative
neural stem cells), and MCM2 (involved in DNA replication at the
G1 phase of the cell cycle, and expressed by neural stem cells). We
used these three markers to identify cells undergoing cell division,
and to identify what proportion were committed to the glial
lineage, as evidenced by Sox2 expression, and how many were
neural precursors/stem cells based on expression of d-GFAP. The
results revealed statistically significantly greater numbers of Sox2-
positive cells (70.8763.33 normal vs 124.8565.79 DBS;
P= 0.024; Figure 2a, b, g) and d-GFAP-positive cells
(19.6362.37 normal vs 29.1361.68 DBS; P= 0.040; Figure 2c,
d, f) in PD-DBS brain tissue samples compared with normal brain
tissue samples, specifically in the 3rd ventricle. Such a difference
was also seen for the numbers of MCM2-immunoreactive cells,
specifically in the peri-lead (or equivalent in non-DBS cases) region
(Figure 2g, P = 0.048). These differences in the numbers of
proliferative cells expressing MCM2 and Sox2 in DBS brains were
supported by qPCR results, which revealed higher levels of
expression of Sox2 and MCM2 genes in the lining of the third
ventricle and peri-lead area, respectively, in PD-DBS tissue
compared with normal tissue (Figure 3). Together, these findings
support the hypothesis that DBS treatment induces proliferation
around the DBS lead tip, and stimulates cell division in the SVZ,
as shown by the higher levels of expression of genes specifically
expressed in neural precursor/stem cells.
Discussion
This study revealed differences in the numbers of precursor cells
in the SVZ overlying the caudate nucleus, the third ventricle and
the peri-DBS lead region among post-mortem human PD, PD-
DBS, and normal brains. The results indicate the presence of
higher numbers of SVZ precursor cells (lining of the lateral
ventricle and third ventricle) in DBS brains compared with normal
and untreated PD brains. Thus, the intriguing hypothesis arises
that the DBS electrodes acted as a stimulant to induce cell
proliferation resulting in increased numbers of SVZ precursor cells
adjacent to the caudate nucleus, the lining of the third ventricle
and the peri-lead regions. The neurodegeneration and transmitter
deficiencies associated with PD produce critical disruptions in the
activity of a family of basal ganglia circuits known to impact motor
and non-motor dysfunction [24]. The neuromodulation of
abnormal activity in these circuits through the use of such
technologies as DBS can produce important symptomatic benefits
and, as we have shown in this study, possibly also alter brain
cellular architecture [21]. Our results for the first time provide
evidence that apart from the symptomatic relief provided by PD
DBS, there is increased proliferation of neural precursor cells in
the adult human brain in response to DBS electrode implantation
together with electrical stimulation. It is important to keep in mind
that there is a very close proximity between the region of
stimulation (STN or GPi) and the ventricular system; hence, it
would be reasonable to suggest that there is migration of immature
Figure 1. Increased PCNA labeling in the SVZ after deep brain stimulation compared with normal or PD-only brains. a. Demonstrates
diagrammatically the localization and placement of a deep brain stimulation electrode very close to the subthalamic nucleus just below the globus
pallidus. The deep brain stimulation electrode lead sits within close proximity of the lateral and third ventricles. Diagram labeling is as follows:
1 = lateral ventricle, 2 = third ventricle, 3 = subthalamic nucleus, 4 = globus pallidus and 5= deep brain stimulation electrode. b. Graph shows the
mean numbers of PCNA-positive cells in the SVZ adjacent to the caudate nucleus of normal, PD and DBS brains. The graph shows a significantly
greater number of PCNA-positive cells in brains that received DBS treatment compared with normal brains, but there was no significant difference in
the numbers of PCNA-positive cells between normal and PD brains. c–e. Overall, the DBS cases show significantly greater mean numbers of PCNA-
positive cells compared with normal and PD brains. The figures below the graph illustrate PCNA-positive immunolabelling in the SVZ adjacent to the
caudate nucleus of normal, PD and PD-DBS brains. PD-DBS brains had an expanded SVZ compared with normal and untreated PD brains. Scale
bar = 100 mm f–i. Demonstrates double labeling of PCNA (red) together with d-GFAP (green) and Hoechst (blue) labeling in the SVZ of a PD-DBS
brain. Scale bar = 10 mm.
doi:10.1371/journal.pone.0088770.g001
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Figure 2. Sox2, MCM2 and d-GFAP are increased in specific brain regions in PD-DBS brains. The figures illustrate Sox 2-positive labeling in
the ependymal layer, adjacent to the hypothalamus, of (a) DBS and (b) normal brains (in all figures red = autofluorescent blood cells, green= Sox2 or
d-GFAP). The graph (e) shows the mean numbers of Sox2-positive cells in the ependymal layer in normal (negative), and DBS (positive) brain tissue
samples. Overall, the DBS-positive cases show a statistically significant difference in the mean numbers of Sox2-positive cells. Scale bar is equivalent
for figures a–d= 100 mm. (c) The figures illustrate d-GFAP positive labeling in the ependymal layer, adjacent to the hypothalamus of DBS and (d)
normal brains. (e–g) Boxplots of the cell count data by group. The bold horizontal lines indicate the group medians. The top and bottom of the boxes
represent the 75th and 25th percentiles, respectively. An asterisk indicates an outlying data point (a point farther above or below the box than 1.56
the box height). The graph (e) shows the mean number of Sox2-positive cells in the ependymal layer in normal and PD-DBS brain tissue samples. The
graph (f) shows the mean number of d-GFAP-positive cells in the ependymal layer in normal and PD-DBS brain tissue samples. The graph (g) shows
the mean number of MCM2-positive cells in the peri-lead region in normal and PD-DBS brain tissue samples.
doi:10.1371/journal.pone.0088770.g002
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NSC-like cells from the SVZ into the peri-DBS region. To date, all
of the studied populations of migratory cells have produced glia or
interneurons in their target locations; therefore, it is most likely
that any neuroblasts that migrate toward the electrode would also
become glia or interneurons. However, the possibilities to study
this directly are limited because of the temporal loss of migratory
and proliferation markers as the neuroblasts become neurons.
There are several pathways that project afferently and efferently to
the STN and to the striatum, and these pathways could possibly
communicate with the SVZ and innervate type C cells, which
would potentially drive them to proliferate in the SVZ region [19].
This hypothesis remains speculative. The precise area of tissue
stimulation has been estimated and modeled but not specifically
measured in all of the tissue that surrounds the activated electrode.
However, it is clear from diffusion tensor imaging studies and
electrophysiological studies that the extent of spread of stimulation
from the activated electrodes is dependent on the number of
heavily myelinated fibers in the peri-electrode region. Under
normal circumstances tissue activation is estimated to occur up to
4–5 mm away from the electrode tip [25,26]. The distance from
the medial aspect of the STN to the third ventricle is 4–7 mm
[27]. This close proximity, therefore, makes it possible that the
higher levels of proliferation observed are a direct effect of DBS.
We cannot rule out the possibility that electrode insertion plays a
role in the observed findings given that any puncture injury to the
brain elicits a short-term (up to about 14 days) proliferative
response. However, we have studied the brain of PD-DBS patients
that died some considerable time (ranging from 0.5 to 6 years)
after electrode placement, and thus, it is unlikely that the increase
in progenitor proliferation is a result of the initial surgical
intervention [28,29]. We also cannot rule out the possibility that
chronic electrode placement leads to the proliferative response
seen. The mechanism of action of the high-frequency stimulation
employed in DBS has not yet been fully unraveled, although DBS
has been used clinically to treat PD for over two decades. Most
experts believe that DBS acts in both inhibitory and excitatory
fashions, and that, in addition to physiological changes, there is
propagation of a calcium wave that leads to neurotransmitter
release and changes in blood flow. Based on these possible effects
of DBS, there are four main hypotheses that have been proposed
to explain the mechanism of action of DBS: synaptic inhibition
[4], synaptic depression [30], depolarization blockade [31], and
modulation of network activity induced by stimulation [32]. There
is one report indicating that STN DBS is neuroprotective, or has
disease- modifying effects, although this is a topic that is highly
debated in the field [3]. If disease modification does occur as a
result of DBS, we know that it must be minimal, as PD is known to
progress despite DBS [33,34]. If disease modification did occur on
a small scale, our hypothesis would be that it is achieved, at least in
part, due to the proliferative effect of the electrical stimulation in
the NSC/precursor cell compartment in the adult brain. Although
our observations of proliferative NSCs are insufficient to argue for
the prevention of the progression of PD, they do provide a possible
strategy to stimulate a system that can endogenously repair the
Figure 3. Sox2 and MCM2 gene expression is increased in the lining of the third ventricle and per-lead region in PD-DBS brains.
Boxplots of gene expression relative to 18S for Sox2: control and PD-DBS groups. The permutation test p-value shows that the expression level is
significantly higher in the PD-DBS group at the 0.05 level. Boxplots of expression relative to 18S for MCM2: control and PD-DBS groups. The
permutation test p-value shows that the expression level is significantly higher in the PD-DBS group at the 0.05 level. The relative gene expression
level was normalized on the basis of the expression of a reference gene (18S) and was also normalized on the basis of the expression of a reference
sample (calibrator). Final results are expressed in arbitrary units in gene expression relative to the expression of 18S gene and calibrator sample. The
relative expression was calculated by 22DDCT, where CT= fluorescence threshold value; DCT=CT of the target gene – CT of the reference gene (18S);
DDCT=DCT of the treated sample – DCT of the reference sample. A pool of five normal tissue samples served as the reference sample. The increased
levels of gene expression of Sox2 and MCM2 correlate with the immunolabelling and cell count data.
doi:10.1371/journal.pone.0088770.g003
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damaged brain. It is our hope that, through these findings,
endogenous neural stem cell proliferation and potential mobiliza-
tion from germinal niches can in the future be harnessed for the
treatment of neurodegenerative diseases such as PD, Alzheimer’s
disease, Huntington’s disease, amyotrophic lateral sclerosis,
dystonia, and stroke.
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